Kristie L. Kahl

In this week’s episode of the CURE Talks Cancer podcast, we spoke with a childhood cancer survivor about her journey with stage 4 neuroblastoma, and also about taking part in the St. Jude LIFE research program.

The Food and Drug Administration granted a priority review to Tibsovo (ivosidenib) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who are not eligible for standard therapy.

The Food and Drug Administration granted a priority review to Keytruda (pembrolizumab) for the third-line treatment of patients with advanced small cell lung cancer (SCLC).

Vofatamab (B-701) may be safe and effective for patients with locally advanced or metastatic bladder cancer with an FGFR3 mutation who have relapsed after, or are refractory to, at least one prior line of chemotherapy, according to preliminary findings.

The Food and Drug Administration granted a priority review to polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The Food and Drug Administration (FDA) granted a priority review to entrectinib for the treatment of adult and pediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors and for metastatic, ROS1-positive non-small cell lung cancer.

The Food and Drug Administration granted a priority review to Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as a frontline treatment for advanced renal cell carcinoma.

This week, we spoke with FORCE to dispel some of the misconceptions associated with at-home genetic testing for hereditary cancer risk.

An integrative model helped to determine which patients with bladder cancer may benefit from checkpoint inhibitor therapy.

CURE® spoke with CEO Linda Tantawi about addressing the needs of underserved communities and how education is key in helping women in the Greater New York City area.

The Food and Drug Administration granted a priority review to Bavencio (avelumab) in combination with Inlyta (axitinib) to treat patients with advanced renal cell carcinoma (RCC).

Imbruvica (ibrutinib) may be superior to standard of care in elderly patients with untreated chronic lymphocytic leukemia (CLL), according to phase 3 findings published in the New England Journal of Medicine.

The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Check out this week’s quick overview of what is making headlines in the cancer space.

This week, we spoke with two faculty members from the patient-focused meeting at the upcoming Miami Breast Cancer Conference.

Researchers are evaluating the use of folate receptors to treat platinum-resistant ovarian cancer.

Meeting combined exercise guidelines improved quality of life in kidney cancer survivors; however, few individuals reported that they actually follow such guidelines.

The Food and Drug Administration approved Imbruvica plus Gazyva for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

In this week’s episode of CURE Talks Cancer, we spoke with two doctors honored for their efforts to improve the quality of life for those affected by chronic lymphocytic leukemia (CLL).

23andMe received Food and Drug Administration (FDA) clearance for a genetic health risk report on a hereditary colorectal cancer syndrome, according to the genetics company.

A man with glioblastoma has received Gliovac (ERC1671) under legislation allowing for the terminally ill to try experimental drugs that have passed preliminary FDA testing.

Older adults may be at an increased risk for a heart attack or stroke five months before they are even diagnosed with cancer – a risk that peaked in the month prior to diagnosis, according to a report published in Blood.

A recent survey demonstrated the common tradeoffs most patients report regarding treatment decisions, highlighting the importance of shared decision making.

The Food and Drug Administration has accepted Roche’s supplemental biologics license application for Tecentriq (atezolizumab) plus chemotherapy for the frontline treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations.

The Food and Drug Administration approved Cabometyx (cabozantinib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib).

This week, we spoke with the co-founder of a nonprofit organization dedicated to funding research to eliminate childhood cancer, as well as two families who have benefitted from the research being done in this area.

The Raymond Foundation released the Cancer Caregiver Action Plan to help others with emotional support and information.

In an interview with CURE, Filippo Milano, M.D., Ph.D., explains what cord blood transplantation is and why it is important for patients to learn more.

Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.

The Food and Drug Administration (FDA) approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm in adults and in pediatric patients aged 2 or older.